Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
The Journal of Pharmacy and Pharmacology
|
November 9, 2011
Ergosta-4,6,8(14),22-tetraen-3-one isolated from Polyporus umbellatus prevents early renal injury in aristolochic acid-induced nephropathy rats
Ying-Yong Zhao, Li Zhang, Jia-Rong Mao, et al.
Bioanalysis
|
April 15, 2015
Urinary metabolomics and biomarkers of aristolochic acid nephrotoxicity by UPLC-QTOF/HDMS
Ying-Yong Zhao, Dan-Dan Tang, Hua Chen, et al.
Plos One
|
May 26, 2016
Retrospective Study of Phospholipase A2 Receptor and IgG Subclasses in Glomerular Deposits in Chinese Patients with Membranous Nephropathy
Hong-Rui Dong, Yan-Yan Wang, Xiao-Hong Cheng, et al.
Nature Communications
|
January 20, 2022
A case of antiferrochirality in a liquid crystal phase of counter-rotating staircases
Ya-Xin Li, Hong-Fei Gao, Rui-Bin Zhang, et al.
Expert Review of Anti-Infective Therapy
|
January 22, 2024
Drug recommendation for optimization on treatment outcome for MDR/RR-TB based on a multi-center, large scale, retrospective cohort study in China
Lin Fan, Ming Yang, Yu-Tong Han, et al.
Nature Communications
|
April 2, 2019
Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan
Dan-Qian Chen, Gang Cao, Hua Chen, et al.
Chinese Journal of Integrative Medicine
|
November 24, 2018
Effects of Niaoduqing Particles () on Delaying Progression of Renal Dysfunction: A Post-trial, Open-Label, Follow-up Study
Ying Zheng, Nian-Song Wang, Yu-Ning Liu, et al.
Chinese Medical Journal
|
October 21, 2017
Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study
Ying Zheng, Guang-Yan Cai, Li-Qun He, et al.
Journal of Integrative Medicine
|
February 16, 2021
Efficacy and safety of Shenyankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: A multicenter randomized controlled trial
Jie Wu, Shu-Wei Duan, Hong-Tao Yang, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
The Journal of Pharmacy and Pharmacology
|
November 9, 2011
Ergosta-4,6,8(14),22-tetraen-3-one isolated from Polyporus umbellatus prevents early renal injury in aristolochic acid-induced nephropathy rats
Ying-Yong Zhao, Li Zhang, Jia-Rong Mao, et al.
Bioanalysis
|
April 15, 2015
Urinary metabolomics and biomarkers of aristolochic acid nephrotoxicity by UPLC-QTOF/HDMS
Ying-Yong Zhao, Dan-Dan Tang, Hua Chen, et al.
Plos One
|
May 26, 2016
Retrospective Study of Phospholipase A2 Receptor and IgG Subclasses in Glomerular Deposits in Chinese Patients with Membranous Nephropathy
Hong-Rui Dong, Yan-Yan Wang, Xiao-Hong Cheng, et al.
Nature Communications
|
January 20, 2022
A case of antiferrochirality in a liquid crystal phase of counter-rotating staircases
Ya-Xin Li, Hong-Fei Gao, Rui-Bin Zhang, et al.
Expert Review of Anti-Infective Therapy
|
January 22, 2024
Drug recommendation for optimization on treatment outcome for MDR/RR-TB based on a multi-center, large scale, retrospective cohort study in China
Lin Fan, Ming Yang, Yu-Tong Han, et al.
Nature Communications
|
April 2, 2019
Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan
Dan-Qian Chen, Gang Cao, Hua Chen, et al.
Chinese Journal of Integrative Medicine
|
November 24, 2018
Effects of Niaoduqing Particles () on Delaying Progression of Renal Dysfunction: A Post-trial, Open-Label, Follow-up Study
Ying Zheng, Nian-Song Wang, Yu-Ning Liu, et al.
Chinese Medical Journal
|
October 21, 2017
Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study
Ying Zheng, Guang-Yan Cai, Li-Qun He, et al.
Journal of Integrative Medicine
|
February 16, 2021
Efficacy and safety of Shenyankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: A multicenter randomized controlled trial
Jie Wu, Shu-Wei Duan, Hong-Tao Yang, et al.
Page
of 2